AstraZeneca and Absci's AI Alliance in Cancer Antibody Research
AstraZeneca partners with AI firm Absci in a groundbreaking $247 million venture to develop advanced cancer-fighting antibodies, marking a significant stride in AI's integration with healthcare research.
